donepezil + perphenazine

Donepezil + perphenazine is a combination of two pharmaceutical agents used together, primarily in research or off-label clinical settings, for the management of neuropsychiatric symptoms in patients with dementia, particularly Alzheimer's disease. Donepezil is an acetylcholinesterase inhibitor that increases acetylcholine levels in the brain and is indicated for the treatment of mild to severe Alzheimer's disease. Perphenazine is a typical antipsychotic (a piperazinyl phenothiazine) that acts as a dopamine D1/D2 receptor antagonist and is used to manage psychotic disorders and severe nausea/vomiting. The rationale for combining these drugs stems from evidence suggesting that donepezil may augment the efficacy of antipsychotics like perphenazine in controlling psychosis-related symptoms (such as delusions and hallucinations) in dementia patients who do not respond adequately to neuroleptic monotherapy or experience intolerable side effects. This combination has been studied for its potential to improve mental state while reducing extrapyramidal side effects compared to antipsychotic monotherapy[1][3]. However, this combination does not have an established fixed-dose commercial product or unique brand name.